Details

Autor(en) / Beteiligte

• Rosell, Rafael
• Moran, Teresa
• Queralt, Cristina
• Porta, Rut
• Cardenal, Felipe
• Camps, Carlos
• Majem, Margarita
• Lopez-Vivanco, Guillermo
• Isla, Dolores
• Provencio, Mariano
• Insa, Amelia
• Massuti, Bartomeu
• Gonzalez-Larriba, Jose Luis
• Paz-Ares, Luis
• Bover, Isabel
• Garcia-Campelo, Rosario
• Moreno, Miguel Angel
• Catot, Silvia
• Rolfo, Christian
• Reguart, Noemi
• Palmero, Ramon
• Sánchez, José Miguel
• Bastus, Roman
• Mayo, Clara
• Bertran-Alamillo, Jordi
• Molina, Miguel Angel
• Sanchez, Jose Javier
• Taron, Miquel

Titel

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Ist Teil von

• The New England journal of medicine, 2009-09, Vol.361 (10), p.958-967

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• Lung cancers with a mutation in the EGFR gene have heightened sensitivity to tyrosine kinase inhibitors. Asian patients have been the most intensively studied population for such mutations and for responsiveness to tyrosine kinase inhibitors. This study shows that large-scale screening for EGFR mutations in a European population is feasible and can influence decisions about treatment of advanced lung cancer. This study shows that large-scale screening for EGFR mutations in a European population is feasible and can influence decisions about treatment of advanced lung cancer. Molecular-profiling studies indicate that activating mutations in the epidermal growth factor receptor ( EGFR ), PI3K , BRAF, and K-ras genes are generally nonoverlapping and identifiable in approximately 40% of non–small-cell lung cancers. These mutations, plus others that contribute to tumor progression (“driver” mutations), can be found in almost half of all non–small-cell lung cancers. 1 , 2 The two proto-oncogenes that are most commonly mutated in pulmonary adenocarcinomas are K-ras and EGFR . Nearly 90% of lung-cancer–specific EGFR mutations comprise a leucine-to-arginine substitution at position 858 (L858R) and deletion mutants in exon 19 that affect the conserved sequence LREA (delE746-A750). 3 – . . .